Augusta

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• HIV3 trials
• Lung cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Liver and biliary tract cancer1 trial
• Lupus (SLE)1 trial
• Melanoma1 trial

Phase

• Phase 34 trials
• Phase 12 trials
• Phase 21 trial

Status

• Active, not recruiting5 trials
• Completed2 trials

Lead sponsor

• Tesaro, Inc.3 trials
• ViiV Healthcare3 trials
• GlaxoSmithKline1 trial

Running trials

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Tesaro, Inc.· Source

• Active, not recruiting

  Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

  NCT03299049· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

  NCT02938520· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

  NCT02817633· Phase 1· Tesaro, Inc.· Source

• Active, not recruiting

  Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

  NCT02715284· Phase 1· Tesaro, Inc.· Source

Closed trials

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

  NCT01649765· Phase 2· GlaxoSmithKline· Source